Cabinet Particular Policlinic Algomed S.R.L. — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

Cabinet Particular Policlinic Algomed S.R.L.

Location

Timisoara, Romania

Identifier

ORG-100047063

Address

Strada Blaga Lucian Nr 4, 300002, Romania

Departments

Departament Clinic de Medicina Interna si Gastroenterologie
Gastroenterologie
Gastroenterology
Gastroenterology Department

Clinical trials at this site (9)

Search interface

A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending

2025-522511-42-00 Crohn's disease 4
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Moderate to Severely Active Ulcerative Colitis & Modera 4 2025-08-27
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Crohn's disease 4 2025-04-07
A Phase 2b Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects with Moderately to Severely Active Crohn’s Disease Recruiting

2023-506704-14-00 Moderately to Severely Active Crohn's Disease 4 2024-09-04
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended

2023-506769-67-00 Moderate to Severely Active Ulcerative Colitis 4 2024-09-04
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
A Placebo controlled Maintenance and Long-term Extension Study of the Efficacy and Safety of Risankizumab in Participants with Crohn's Disea… Ended

2023-506399-28-00 Crohn's Disease 5 2017-11-08
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comple… Ended

2023-504951-29-00 Chron's Disease 5 2017-07-27
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29